But the letter from Chaffetz and Cummings sent to Bresch on Monday clearly had a problem with that claim.
"Mylan claimed an estimated tax impact of $187 million for EpiPens in 2015," the letter said. "That estimate is nearly three times Mylan's companywide income tax provision that year — $67.7 million — as reported in its annual SEC filing."
"That figure reflected $93 million in non-U.S. taxes offset by U.S tax benefit of $25.9 million." (Emphasis from the document.)
The letter cites a Washington Post article that says the 37.5 percent U.S. tax rate is "more than five times the overall tax rate the company actually paid last year, and much higher than its actual U.S. tax rate, which tax specialists have pegged at close to zero."
The letter notes that during Bresch's testimony, she frequently referred to a graphic, entitled "EpiPen AutoInjector Estimated Profitability," which identified a a set of factors that reduce the product's profit margin, including "rebates & allowances," "cost of goods sold" and "direct EpiPen Auto-Injector costs."
But, the letter said, "the graphic makes no mention of taxes or the tax assumption used by Mylan to estimate the $100 profit number. Neither did your written testimony."
"The only time you mentioned taxes during the hearing was to disclose that Mylan's companywide effective tax rate is between 15 and 17 percent, as a result of Mylan's decision to move its headquarters overseas," the letter from Chaffetz and Cummings noted.
The letter also said that Mylan didn't directly reference its tax assumption for its EpiPen profit estimates in either a Sept. 15 letter to the committee, or in documents the company produced.
Chaffetz and Cummings wrote that failure to disclose the tax assumptions, "despite opportunities to do so ... raises questions." Their letter pointed out that Chaffetz said during the hearing that Mylan's "dumbed down financials" don't make sense without explanation, and that Cummings had said, "your numbers don't add up."
"And it is extremely difficult to believe that you are making only $50 profit [per EpiPen] when you just increased the price by more than $100 per pen," Cummings had said during that hearing.
Mylan on Monday noted that it said last week that "just as we did not use a blended global tax rate, we also did not allocate corporate expenses associated with running the business, which would have further reduced [EpiPen's] profitability."
"We believe it is most appropriate, and conservative, to focus entirely on EpiPen Auto-Injectors specific costs and associated taxes," the company said.
— Additional reporting by CNBC's Meg Tirrell.